Latest Earnings Results: Q2 '26
Estimated EPS
-$0.15
Reported EPS
-$0.16
Surprise
-9.8%
Estimated Rev
$49.16M
Reported Rev
$47.3M
Surprise
-3.78%
• Reported GAAP EPS of -$0.16 down -166.67% YoY • Reported revenue of $47.28M down -24.01% YoY • LifeMD expects full year 2026 revenue of $205.5 million to $212.5 million and adjusted EBITDA of negative $6.0 million to breakeven, including launch costs for the XYOSTED auto-injector product.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.15 | -- | -- | N/A |
Q2 '26 | -$0.15 | -$0.16 | -9.80% | MISSED |
Q1 '26 | -$0.21 | -$0.20 | 2.78% | BEAT |
Q4 '25 | -$0.07 | $0.41 | 723.92% | BEAT |
Q3 '25 | -$0.02 | -$0.10 | -400.00% | MISSED |